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Abstract
Background: Polymorphisms in CCR5, the major coreceptor for HIV, and CCL3L1, a potent CCR5 ligand and HIV-suppressive
chemokine, are determinants of HIV-AIDS susceptibility. Here, we mathematically modeled the potential impact of these
genetic factors on the epidemic spread of HIV, as well as on its prevention.
Methods and Results: Ro, the basic reproductive number, is a fundamental concept in explaining the emergence and
persistence of epidemics. By modeling sexual transmission among HIV+/HIV2 partner pairs, we find that Ro estimates, and
concordantly, the temporal and spatial patterns of HIV outgrowth are highly dependent on the infecting partners’ CCL3L1-
CCR5 genotype. Ro was least and highest when the infected partner possessed protective and detrimental CCL3L1-CCR5
genotypes, respectively. The modeling data indicate that in populations such as Pygmies with a high CCL3L1 gene dose and
protective CCR5 genotypes, the spread of HIV might be minimal. Additionally, Pc, the critical vaccination proportion, an
estimate of the fraction of the population that must be vaccinated successfully to eradicate an epidemic was ,1 only when
the infected partner had a protective CCL3L1-CCR5 genotype. Since in practice Pc cannot be .1, to prevent epidemic
spread, population groups defined by specific CCL3L1-CCR5 genotypes might require repeated vaccination, or as our models
suggest, a vaccine with an efficacy of .70%. Further, failure to account for CCL3L1-CCR5-based genetic risk might confound
estimates of vaccine efficacy. For example, in a modeled trial of 500 subjects, misallocation of CCL3L1-CCR5 genotype of only
25 (5%) subjects between placebo and vaccine arms results in a relative error of ,12% from the true vaccine efficacy.
Conclusions: CCL3L1-CCR5 genotypes may impact on the dynamics of the HIV epidemic and, consequently, the observed
heterogeneous global distribution of HIV infection. As Ro is lowest when the infecting partner has beneficial CCL3L1-CCR5
genotypes, we infer that therapeutic vaccines directed towards reducing the infectivity of the host may play a role in halting
epidemic spread. Further, CCL3L1-CCR5 genotype may provide critical guidance for optimizing the design and evaluation of
HIV-1 vaccine trials and prevention programs.
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Introduction
For more than 25 years, HIV-1 infection has been spreading
across human populations relentlessly. An improved understand-
ing of the factors that promote viral spread and an effective
vaccine is required to halt this pandemic. Significant attention has
been placed on elucidating the impact of the HIV-1 genotype on
the spread of infection and on development of an HIV vaccine.
Although much less is known about the impact of host factors on
these events, several reasons suggest that their contribution might
be large. The spread of HIV in the general population is a product
of the susceptibility of uninfected persons and the communicability
of HIV from the infected person [1,2,3]. This communicability is,
in part, reflected by infectivity of the host as measured by the
plasma RNA viral load (VL) [1,2,3,4,5,6]. However, we and others
have demonstrated that susceptibility and communicability are
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susceptibility ([7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23]
and reviewed in [24,25,26,27,28,29]). For this reason, we
hypothesized that the inherent variability among individuals
in host genes that influence HIV-AIDS susceptibility, when
translated to the level of a population, might influence the
epidemic spread of HIV in that population and, by extension,
might contribute to the observed heterogeneous distribution of
HIV among populations [3,30,31,32,33,34,35,36,37,38]. We
also posited that if evidence in support of this hypothesis were
to be found, it might have implications for the possibility that
failure to account for host factors that influence HIV-AIDS
susceptibility may pose a challenge in designing public health
measures to curb the epidemic, including evaluation of the
efficacy of a vaccine. This was relevant in light of data
from a recent HIV vaccine trial where vaccination was
associated with an increased risk of acquiring HIV infection
[39,40,41,42,43,44].
We selected two candidate genes to test our hypotheses: those
coding for CC chemokine receptor 5 (CCR5), the major HIV
coreceptor [45,46], and CC chemokine ligand 3-like 1 (CCL3L1),
the most potent CCR5 ligand and HIV-suppressive chemokine
[47,48,49,50,51,52]. In previous studies, we and others found that
the copy number of the CCL3L1-containing segmental duplica-
tions and/or genotypes of CCR5 were determinants of inter-
individual differences in several parameters: cell-mediated immu-
nity (CMI) as assessed by delayed-type hypersensitivity (DTH) skin
test reactivity in both HIV-negative and -positive individuals [53];
HIV acquisition [7,8,9,20,54,55,56,57]; events established during
the early stages of the infection such as the magnitude of initial
CD4+ T-cell depletion and the extent of viral replication as
reflected by the steady-state plasma HIV RNA VL (VL setpoint)
[20,53,58]; rate and extent of CD4+ T cell depletion during
disease course and, consequently, risk and rate of AIDS
development [7,8,10,11,13,14,15,20,24,25,26,27,28,53,58] and
recovery of CD4+ T cells during HAART [58,59,60,61]. Others
have also found a relationship between the copy number of
CCL3L1-containing segmental duplications and viral load and
HIV-specific CD4+ and CD8+ T cell responses [55,62]. However,
we also found that the CCL3L1 gene dose and CCR5 genotypes
affected risk and rate of developing AIDS independent of their
effects on the VL or CMI as assessed by DTH skin test reactivity
[53,63]. The latter findings indicated that only a portion of the
disease-modifying effects associated with these two host factors on
HIV-AIDS susceptibility can be captured by assessing the plasma
VL or a surrogate marker of CMI. The nature of these
unmeasured effects is currently unknown.
Factors that influence the magnitude of the events that are
established during the early stages of infection have important
public health relevance, as the rate of transmission is highest
during this phase of the infection [3,64]. Furthermore, CMI is a
critical antiviral host response [65]. Thus, we surmised that by
affecting CMI in HIV-negative and -positive individuals, viral
entry, early events, and other unmeasured parameters, CCL3L1-
CCR5 genotypes might affect risk of HIV acquisition and disease
progression rates for an individual patient, while at the level of
populations they might modify the propagation and maintenance
of the HIV pandemic and consequently, they may impact on
preventive interventions. To examine this possibility, we used
modeling approaches to determine whether genetic variations in
CCL3L1-CCR5 can serve as a biological basis for distinct
subtrajectories of the HIV epidemic in a population, and whether
accounting for the CCL3L1-CCR5 genetic makeup of vaccine trials
could provide a more precise estimate of the critical proportion of
the population-based vaccination coverage required to limit the
epidemic, as well as vaccine efficacy.
Results
Modeled impact of CCL3L1-CCR5 genetic risk groups
(GRG) on the epidemic
Based on possession of a low or high copy number of CCL3L1
(CCL3L1
low or CCL3L1
high) and detrimental or nondetrimental
CCR5 genotypes (CCR5
det and CCR5
non-det) we assigned the
polymorphisms in these two genes into four groups [20]. Based
on their associations with a low, moderate and high risk for disease
progression rates to AIDS and death in a portion of the U.S.-based
DoD HIV Natural History Study cohort [20], we designated these
genotypes as low, moderate and high genetic risk groups (GRG;
Figure 1a) [53,58].
We examined the population-level impact of CCL3L1-CCR5
GRG status within the rubric of an epidemiologic parameter,
designated as Pc, as well as other relevant epidemiologic
parameters. The description of these parameters and their
derivations are described in Supplementary online material
S1 (SOM) section 1. The critical vaccination proportion or Pc is
an important estimate of the fraction of the population that must
be vaccinated successfully to eradicate an epidemic. The
mathematical components of Pc are shown in Figure 1b along
with the possible points at which GRG status might affect this
Figure 1. Conceptual model by which CCL3L1-CCR5 genotypes
might influence the prevention and epidemic outgrowth of
HIV infection. (a) Classification system used to categorize the copy
number of CCL3L1 (low or high) and genotypes of CCR5 (detrimental or
nondetrimental) into three (low, moderate and high) risk categories. (b)
Conceptual model by which the GRGs might affect epidemiological
endpoints. The endpoint Pc has different components, and those that
might be influenced by the GRGs are shown in green-colored letters,
i.e., Ro, e and f. The model assumptions, parameters and methods are
described in Supplementary Online Materials S1 (SOM), section
1 and Table S1. The conceptual model assumes a vaccine that requires
the induction of CMI, in part, for protection. Here, the formula of Pc is
from studies by Anderson [1] and Blower [2]. ?, indicates possible
additional effects associated with CCL3L1-CCR5 GRGs that are unmea-
sured [53,63].
doi:10.1371/journal.pone.0003671.g001
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Figure 1b shows that the GRGs might influence the estimate of Pc
primarily by influencing infectiousness and susceptibility, and
possibly by also affecting responses to vaccines that rely on the
generation of CMI. One important component of Pc is the basic
reproductive number (Ro)( Figure 1b). Effective human-to-
human transmission of an infectious agent requires that Ro should
exceed one, where Ro is the average number of secondary
infections arising from one infected individual in a completely
susceptible population [66]. Thus, the epidemic threshold is
Ro=1, above which the disease spreads and below which it
eventually dies out. Given that variations in CCL3L1-CCR5 are
associated with altered HIV susceptibility and/or communicabil-
ity, we first used highly conservative assumptions to model the
effects of the CCL3L1-CCR5 GRGs on Ro.
We modeled sexual transmission, and based on the GRG status
of the infected and uninfected partner pair, the overall population
can be divided into nine partner-pair population groups
(Figure 2a). We determined the distribution of the GRG-defined
partner pairs from the prevalence (parenthesis) of the low (50%),
moderate (42%) and high (8%) GRG status in a large US-based
cohort of mixed ethnicity [20]. Assuming random mixing among
individuals in the general population, the GRG-defined partner
pairs in which one member has a low and moderate GRG
constituted nearly 88% of the population, i.e., group numbers 1, 2,
4 and 5 (Figure 2a). In all but one (group #1) of these nine
groups, the Ro was greater than unity (Figure 2b). In partner-pair
groups 1 to 9, Ro increased in a step-wise manner, and this
increase was mostly dependent on the GRG status of the infected
partner (Figure 2b). HIV+/HIV2 partner pairs defined by a
low-low, moderate-moderate, and high-high GRG status — that
is, partner-pair population groups 1, 5 and 9 — were associated
with the least, intermediate and highest Ro, respectively (Figure 2a
and Figure 2b).
Since Ro is a fundamental concept in explaining the emergence
and persistence of epidemics, we next determined whether these
GRG-dependent differences in Ro might also translate into
differences in the rate of epidemic growth (the number of new
infected cases per unit of time) in partner-pair population groups
categorized based on their CCL3L1-CCR5 GRG status
(Figure 2c). In a model that assumes a closed population, the
simulated overall trajectory of the epidemic growth took
approximately ten years to emerge and, without an influx of a
susceptible pool of individuals, predictably, the simulated epidemic
eventually died out (Figure 2c, inset). However, the simulated
trajectories for each of the nine GRG-defined population groups
were strikingly different in three ways: the time point at which an
increase in epidemic growth became evident; the extent of
epidemic growth, i.e., the proportion of subjects infected; and
the duration for which the epidemic persisted (Figure 2c). These
differences in the trajectories in large part tracked the Ro estimates
and were predictably highly dependent on the infecting partner’s
Figure 2. Modeling studies assessing the influence of CCL3L1-CCR5 genotypes on epidemiological parameters relevant to the
outgrowth and prevention of HIV-1. (a) Nine population groups based on the CCL3L1-CCR5 GRG status of sexual partners. The estimated
proportions (prevalence) of the GRGs in the general population are based on data from the HIV-positive WHMC cohort [20]. L, M, and H denote low,
moderate, and high GRG status, respectively. The color codes shown are used to illustrate the nine population groups (Grp) in panels b to g. (b)
Estimates of Ro for the nine color-coded GRG-defined population groups. (c) Simulated epidemic growth in GRG-defined population groups.
Methods are in SOM, section 1.9 online.( d to f) Attributable fractions (AF, panel d), critical response time (CRT, panel e) and Pc (f) in the nine
population groups. The calculations for Pc (f) assume a vaccine efficacy of 50%. (g) Influence of varying vaccine efficacy estimates on Pc in the nine
GRG-defined population. groups shown in panel a. Pc values greater than unity (dashed horizontal line) indicate the point at which repeated mass
vaccination might be necessary. Pc for population group #1 was zero. Additional data relevant to these studies are shown in Table S2 online.
doi:10.1371/journal.pone.0003671.g002
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negligible when the infected partner possessed a low GRG (groups
1t o3 ;Figure 2c). Conversely, the epidemic outgrowth was
maximal when the HIV-infected partner pair possessed a high
GRG (groups 7 to 9; Figure 2c).
The nine GRG-defined population groups together contributed
approximately 45% to the overall epidemic growth (as estimated
by attributable fraction (AF); Figure 2d). However, the relative
contribution of each of the nine GRG-defined population groups
to the overall epidemic varied significantly (0 to 13%). Consistent
with findings shown in Figure 2c, the highest AFs, and
consequently the greatest contribution to the overall epidemic,
were due to infected subjects possessing the moderate or high
GRGs (groups 4 to 9; Figure 2d), i.e., those who are more likely
to be infectious because of higher VLs or have greater
susceptibility to acquiring virus [20,53]. This implies that a
reduction in the population-level viral load – for example, by a
vaccine or HAART – will have the greatest benefit in abating the
spread of the epidemic when applied to these CCL3L1-CCR5
genetically-defined subjects which agrees with the growing view
that a vaccine that can modify disease course by lowering the viral
load setpoint holds promise in curbing epidemic growth of HIV
[1,2,41,67,68,69]. The impact of this strategy could be large, since
these subjects make up nearly 50% of the infected population
(Figure 2a). Additionally, the critical response time (CRT),
defined as the time interval within which the number of epidemic
cases remains stationary (so that interventions implemented within
CRT may be the most effective or the least costly), varied across
the GRGs from 2.59 to 15.3 years (Figure 2e). Thus, these
modeling data suggest that the time available to implement control
measures against spread of the infection may also be highly
dependent on the GRGs.
Finally, using highly conservative assumptions, we considered
the effect of the CCL3L1-CCR5 GRGs on the estimate of Pc.I n
sensitivity analyses, we found that Pc was much more sensitive to
changes in the values of Ro than those of vaccine take (t)o r
durability (d)( Figure 1b)( SOM, section 1.5 online). This
implies that, regardless of the effects of variations in CCL3L1-CCR5
on the eventual immune responses induced by a vaccine, the bulk
of the effects of these genetic factors on Pc will be due to their
effects on Ro. Consistent with this, in a mathematical model in
which the values of vaccine take and durability were held constant,
and assuming a vaccine that has an efficacy of 50%, the Pc
estimates increased with increasing values of Ro (Figure 2f). Pc
was less than unity in the population groups in which the infected
partner possessed a low GRG. Remarkably, Pc was zero when the
both the infected and uninfected partner pair possessed a low
GRG, suggesting that from a purely theoretical perspective this
population group, which constitutes ,30% of the overall
population (Figure 2a), may not require vaccination. By contrast,
Pc was greater than unity in the six population groups in which the
infected partner possessed a moderate or high GRG.
Since in practice Pc cannot be greater than unity, this implies
that to contain the epidemic in population groups where Pc.1
might require repeated immunizations, or vaccination with a more
efficacious vaccine (Figure 2g). For example, our models indicate
that a vaccine with an efficacy of more than 70% would be
required to confer protection by mass vaccination in population
groups 5 to 9 (Figure 2g).
Impact of GRGs on assessment of HIV vaccine efficacy
We considered that failure to account for the transmission-
influencing effects of CCL3L1-CCR5 genotypes might mask true
efficacy estimates of a vaccine that partially blocks transmission
(SOM, section 2). Figure 3a models the effects of misallocating
subjects with respect to their CCL3L1-CCR5 GRG status in the
placebo or vaccine arms of a trial with a preventive vaccine which
has an efficacy of 50%. This mathematical model is relatively
impervious to HIV incidence and trial size number; and it
predicted that, depending on its direction, misallocation will result
in the over- or underestimation of the vaccine’s true efficacy. For
example, in a trial of 500 subjects, for a vaccine that has a 50%
efficacy, misallocation of only 25 (5%) subjects has an estimated
efficacy of 44% (95% confidence interval (CI) of 41%–45%), and
this is a relative error of ,12% (95% CI of 10%–18%) from the
true vaccine estimate (Figure 3a). This effect of GRG-dependent
misallocation is magnified when a vaccine with lower efficacy is
considered in the model (Figure 3b). These effects of misalloca-
tion might be further compounded by the fact that vaccine-
induced CMI might wane faster in subjects who possess the
moderate and high GRGs.
Discussion
The global distribution of HIV among populations is highly
heterogeneous, even in a continent such as Africa
Figure 3. Influence of CCL3L1-CCR5 GRG status on vaccine efficacy. (a) Estimated vaccine efficacy as a function of the percentage of subjects
that are misallocated (m) with respect to their CCL3L1-CCR5 genotype across the placebo or vaccine trial arms. The model is for a preventive vaccine
that has a true efficacy of 50%. The upper line in this plot depicts estimated vaccine efficacy as a function of misallocation of subjects with a low GRG
towards the vaccine arm, resulting in a fallacious increase in the estimated vaccine efficacy. The lower line depicts the converse situation, i.e.,
misallocation of subjects with a low GRG towards the placebo arm, resulting in a fallacious decrease in the estimated vaccine efficacy. (b) Plots depict
the difference (relative error) between the true and estimated vaccine efficacy as a percentage of the true vaccine efficacy for varying values of m.
Methods are described in SOM, section 2.
doi:10.1371/journal.pone.0003671.g003
CCL3L1-CCR5 in HIV-1 Vaccines
PLoS ONE | www.plosone.org 4 November 2008 | Volume 3 | Issue 11 | e3671[3,30,31,32,33,34,35,36,37,38]. Many factors are likely to account
for this heterogeneity, including viral factors, sexual behavior
patterns, sexually transmitted infection, poverty, male circumci-
sion status, unrest and wars, urbanization, and other social and
economic reasons. However, the results of a large ecologic study
indicated that the social, behavioral, economic and political
confounders cannot in themselves account for this heterogeneity
[32]. For example, sexual behaviors between cities in Africa with a
high and low prevalence of HIV were similar [33,34]. Addition-
ally, despite extensive poverty, war and breakdown of health care
systems, the steady-state prevalence of HIV in the Democratic
Republic of Congo, a country near the epicenter of HIV, has
remained remarkably stable and much lower than that of its
neighboring nations [37,38]. Thus, we [13,16,20,70] and others
[18,24,26,32,71,72,73,74,75] have proposed that in addition to
viral and other factors, biologic factors such as the genetic make-
up of populations might contribute to this heterogeneity in the
global distribution of HIV. One of these previous studies used
mathematical modeling to substantiate this possibility [71];
however, the analysis was confined to the contribution of the
CCR5-D32 mutation, which is restricted to individuals of
European descent. By contrast, we have modeled the effects of a
wider range of polymorphisms in CCR5 and the copy number of
CCL3L1 that are determinants of HIV-AIDS susceptibility.
Our findings indicated that under the umbrella of an overall
trajectory of the simulated HIV epidemic (Figure 2c, inset), the
CCL3L1-CCR5 GRG-defined partner pair population groups
discriminate for several distinct subtrajectories with different
shapes and time-scales (Figure 2c). Of these subtrajectories, only
a few appear to be critical in sustaining the epidemic (Figure 2c).
Conversely, these data suggest that human populations that are
enriched for low GRGs, i.e., a high CCL3L1 gene dose and
nondetrimental CCR5 genotypes, might be relatively protected
against the spread of HIV-1. Bolstering this possibility, we recently
found that HIV-infected individuals who maintained very low
viral loads and who were disease free despite not receiving therapy
(elite or viremic controllers of HIV) [76] were selectively enriched
for a low GRG [53]. Given the importance of the VL in
transmission, it is likely that such subjects will transmit virus at very
low rates. Thus, the data indicating that Ro is lowest in HIV+/
HIV2 partner pairs in which the transmitting partner has a low-
risk GRG status suggest that vaccines directed towards reducing
infectivity of the HIV+ host may play an important role in halting
epidemic spread. Underscoring this, findings from animal studies
[67] and mathematical modeling [1,2,68,69] support the hope that
imperfect, T-cell based disease-modifying, i.e., therapeutic vac-
cines, by reducing plasma viral load at the population level might
abate the epidemic.
Thus, the results of our modeling data indicate that there might
be a CCL3L1-CCR5-dependent biological basis for interpopulation
differences in HIV prevalence. We illustrate this concept further
with the example of Pygmies, a distinct population in Central
Africa. The high number of HIV-1 subtypes cocirculating, the
high intrasubtype diversity, and the high numbers of possible
recombinant viruses as well as different unclassified HIV strains
are all in agreement with an old and mature epidemic in Central
Africa, and suggest that these regions are the epicenter of HIV-1
[77,78,79]. The cross-species transmission of simian immunode-
ficiency virus (SIV)cpz to humans is now thought to have occurred
by exposure to the blood of chimpanzees infected with SIVcpz
during hunting and butchering of these primates in Central Africa
[78,79]. The Pygmies, one of the oldest ethnic groups in this area,
have lived in Central Africa for more than 20,000 years. These
hunter-gatherers have been, and continue to be, frequently and
directly exposed to nonhuman primate blood during hunting,
slaughtering and cooking. However, surprisingly, HIV/SIV
infection in Pygmies is rare and occurs mainly after contact with
Bantus rather than from contact with nonhuman primates ([80,81]
and references therein). The rarity of HIV infection via cross-
species transmission from chimpanzee to Pygmies contrasts with
the fact that documented zoonosis of other viruses has occurred
into this population. Data indicates that human T-lymphotropic
virus (HTLV)-1 diversity appears to have resulted from multiple
cross-species transmissions of simian T-lymphotropic virus
(STLVs)-1 following contract between humans and non-human
primate species infected with STLV species [82]. Strikingly,
Pygmies harbor a heterogeneous HTLV-1 strain, which is very
similar to the STLV-1 in chimpanzees (STLV-1cpz) [83]. Might
CCL3L1-CCR5 genetic constitution help explain in part why cross-
species transmission of HIV-1 has been rarely observed in Pygmies
despite evidence of other viral zoonosis? In this respect, it is
noteworthy that compared to other African populations that reside
in geographical proximity (e.g., non-Pygmy Cameroonians),
Pygmies have an even higher frequency of the protective ancestral
CCR5 haplotype designated as HHA [13,16,84] and the gene dose
of CCL3L1 is highest in this isolated population (Figure 4).
Strikingly, all chimpanzees possess the protective ancestral CCR5
haplotype HHA [13,84,85] and a high CCL3L copy number
(Figure 4) [20]. Based on these observations, we conjecture
whether this distinct CCL3L1-CCR5 genetic makeup of Pygmies
might explain the observed relative resistance to cross-species
transfer of HIV-1 but susceptibility to other viral infections, as well
as the lower prevalence of HIV relative to those of neighboring
populations. By analogy, the CCL3L1 and CCR5 genetic makeup
of chimpanzee might afford this nonhuman primate species
protection against disease induced by natural SIV infection as well
as to experimental infection with HIV [86]. The strikingly
monomorphic host CCL3L1-CCR5 genetic constitution of Pygmies
contrasts with the extensive viral heterogeneity prevalent in
Central Africa.
The findings in Figure 2 collectively suggest that the CCL3L1-
CCR5 GRGs play a role in determining not only the dynamics of
the HIV epidemic but also in the design of prevention programs.
We found that Pc was .1 in several HIV+/HIV2 partner pairs
defined by their CCL3L1-CCR5 genotype and that a HIV vaccine
with an efficacy of lower than 70% might be ineffective in
controlling the spread of HIV in these genetically-defined
population groups. This threshold of 70% is also relevant in the
context of three prior observations. First, vaccine acceptability
might be highest when the efficacy is at least 70% [87]; second,
studies that have modeled the effects of a live-attenuated HIV
Figure 4. CCL3L1 copy number (a) and CCR5 HHA haplotype
frequency (b) in Pygmies (N=51) and Cameroonians (N=372).
The prevalence of the chimpanzee CCR5 HHA haplotype and the
ortholog of human CCL3L1 in chimpanzee designated as CCL3L [20], is
also shown (N=83). Error bars in panel a denote 95% confidence
interval.
doi:10.1371/journal.pone.0003671.g004
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around this same threshold [88]; and third, most non-HIV
vaccines in use today have an efficacy between 70 and 90% [89].
Our models consider the possible impact of the CCL3L1-CCR5
GRGs on the evaluation of efficacy estimates of a sterilizing or
prophylactic HIV vaccine. First-generation prophylactic HIV-1
vaccines are unlikely to provide complete protection from infection
[41]. Consequently, there is a thrust to evaluate candidate
imperfect HIV/AIDS vaccines, including those that can stimulate
cell-mediated immune responses that are directed at controlling
viral replication after acquisition of infection [41,90,91,92].
Several of these vaccines are being evaluated in humans (http://
www.iavi.org/). In addition to HIV acquisition, surrogate end-
points currently under consideration for assessment of such
disease-modifying vaccines can be categorized as (a) immunologic,
e.g., maintenance of the CD4+ T-cell counts; (b) virologic, e.g.,
decreased VL set-point; (c) clinical, e.g., reduced numbers of HIV-
infected vaccinated subjects requiring antiretroviral treatment
and/or developing clinical disease; and (d) epidemiological, e.g.,
lower sexual transmission rate by vaccinated subjects who become
HIV-infected subsequent to vaccination [6,93]. However, varia-
tions in CCL3L1-CCR5 by impacting on (i) risk of acquiring HIV
infection, (ii) viral load, (iii) rate and extent of CD4
+ T cell
depletion, and (iii) time from seroconversion to thresholds of CD4
+
T cell counts at which antiviral therapy is initiated might confound
the assessment of the currently used surrogates of vaccine
endpoints.
Additionally, the finding that misallocation of subjects based on
their genetic constitution, modeled here according to CCL3L1-
CCR5 genotypes, might result in fallacious estimates of a vaccine’s
efficacy, has relevance for several reasons. First, it is possible that
confounding due biological factors may influence both the
evaluation and outcome of a vaccine [94]. This is best illustrated
by the results of the STEP trial where antibody titers to
Adenovirus 5 appear to have confounded the outcome and the
interpretation of the efficacy of the virus [39,40,41,42,43,44]. We
have suggested that these higher titers could be due to an
underlying host genetic constitution that may convey a ‘‘stronger
immune system’’ [40]. Additionally, after the failure of two vaccine
trials there is a need to rapidly evaluate vaccine candidates,
especially in smaller numbers of individuals before conducting
larger and more expensive trials. Although our modeling is based
on a randomized trial which is impervious to HIV incidence and
the number of trial participants, the confounding due to
misallocation of favorable or unfavorable genotypes in trial arms
may be important in three scenarios – trials with small sample
sizes; interim analysis of large trials; and trials that demonstrate
equivalence between two candidate vaccines [95]. At least in these
situations the baseline CCL3L1-CCR5 genotyping of the trial
participants might have relevance so as to either resort to a
stratified randomization protocol or to post-allocation adjustment
for the potential influence of the genotypes on vaccine efficacy.
However it is also important to note that large vaccine evaluation
trials (e.g., recent STEP trial) are invariably a composite of subjects
from several different geographically disparate clinical sites, and
consequently, failure to account for CCL3L1-CCR5 genotype at
these smaller sites in subjects with different racial backgrounds
might result in confounding of a larger multicenter trial. This
might be an important point to consider in light of two
observations. First, the CCR5 genotypes that influence AIDS
susceptibility differ according to ethnicity [13,18]. Second, the
high-risk HIV-negative cohorts likely to be recruited for vaccine
trials might be enriched for genotypes that confer protection.
Hence, if a vaccine were to be tested in such subjects it might be
difficult to differentiate between the protective effects of the HIV
vaccine versus those of CCL3L1-CCR5 genotype or other
protective genotypes. Two observations support this possibility:
(i) in a cohort of high-risk female sex workers from South Africa,
we found an enrichment of subjects with high copy numbers of
CCL3L- and CCL4L-containing segmental duplications (Ramsuran
et al, unpublished data); and (ii) a previous study found that there
is an enrichment over time of protective HLA genotypes in a
cohort of East African female sex workers [96].
Thus, taken together, our findings suggest that the inherent
variability among individuals and, by extension, among popula-
tions, in host genes that influence HIV-AIDS susceptibility might
be an important but hitherto underestimated biological challenge
to contend with in the quest for an effective HIV-AIDS vaccine.
Extending the notion of pharmacogenomics, which links host
genetic determinants to variable responses to pharmacologic
agents, we suggest that vaccinogenomics is an equally important
concept to consider in the design and evaluation of vaccines, not
only for established scourges such as HIV-1, tuberculosis, and
malaria, but also for emerging infectious diseases.
Materials and Methods
Our modeling studies used the CCL3L1-CCR5 genotyping data
from the HIV-positive subjects from the Department of Defense
(DoD) HIV Natural History Study (NHS) cohort followed at
Wilford Hall Medical Center (WHMC) and more recently at the
Brooke Army Medical Center (BAMC), San Antonio, TX. The
studied population is the local component of a prospective
multisite observational cohort from the United States Military’s
Tri-Service AIDS Clinical Consortium (TACC) HIV Natural
History Study. Extensive details of this cohort has been provided
elsewhere [13,20,53]. Unidentified cast-off blood from subjects
participating in training at Lackland AFB, TX was used for the
HIV-negative control population. The definitions of all the model
parameters are shown in Table S1.
Pc estimate
For our analyses, we used the conceptual and mathematical
frameworks developed previously for the epidemiological context
of vaccination against HIV-AIDS [1,2]. These models rely on
computing the Pc, which is extensively used as an estimate of the
critical proportion of the population- or cohort-based vaccination
coverage required to limit an epidemic. This estimate has three
main components (Ro, e and f) which are shown in the equation
below.
Pc=[1-(1/Ro)]/ef. Thus, Pc is a function of i) Ro, the basic
reproduction number which provides a measure of the average
number of secondary infections generated by one primary case of
infection in a susceptible population; ii) e, the vaccine efficacy; and
iii) f, the fraction of vaccinated subjects in whom the vaccine effect
does not wane over the period of infectiousness, i.e., the duration
of protection afforded by the vaccine. These three parameters are
shown in Figure 1b, and we have termed f in this figure as vaccine
durability. The relationship among Ro, e and Pc for a fixed f is
shown in the figure in Supplementary Online Materials S1
(SOM), Section 1.1.
We used a deterministic, compartmentalized mathematical
model (Figure 1) to assess the influence of the CCL3L1-CCR5
GRGs on the population dynamics of HIV infection. The
dynamics were based on the estimation of the reproductive
number, Ro. Ro was computed within each CCL3L1-CCR5 GRG-
defined population strata as well as for the overall population, and
detailed methods employed and the assumptions underlying the
CCL3L1-CCR5 in HIV-1 Vaccines
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1.2. We accounted for the possible effect of the CCL3L1-CCR5
GRGs on vaccine efficacy and durability as discussed in SOM,
sections 1.3 and 1.4, respectively. To ensure generalizability of
the results of our modeling studies we also conducted sensitivity
analyses on the model parameters, the results of which are shown
in SOM, section 1.5. Attributable fraction and critical response
time were calculated as described in SOM, sections 1.6 and
1.7, respectively. In our mathematical modeling, we assumed
that the risk behavior and probability of circumcision is not
influenced by CCL3L1-CCR5 GRG status.
Influence of the unequal distribution of CCL3L1 and CCR5
genotypes in trial arms on the estimates of vaccine
efficacy in preventive trials
We simulated a typical randomized two-arm trial design to
examine the influence of the genotypic imbalance across trial arms
on the estimates of HIV vaccine efficacy. The full derivation of the
mathematical model used for estimating this influence is provided
in the SOM, section 2.
Supporting Information
Supplementary Online Material S1 Role of CCL3L1-CCR5
genotypes in the epidemic spread of HIV-1 and evaluation of
vaccine efficac.
Found at: doi:10.1371/journal.pone.0003671.s001 (0.57 MB
DOC)
Table S1 Summary of parameters used to model the influence of
CCL3L1-CCR5 GRGs on epidemiological endpoints. Note, the
inclusion of the parameters of vaccine efficacy and durability were
included on a proof-of-principle basis for vaccines which rely in
part on CMI for their effects.
Found at: doi:10.1371/journal.pone.0003671.s002 (0.03 MB
DOC)
Table S2 Group, indicates subdivision of the population into 9
groups based on their GRGs (Figure 2a). Estimated frequency
indicates the proportion of the population groups from data
derived from the WHMC cohort. The parameters are described in
Supplementary Table S1.
Found at: doi:10.1371/journal.pone.0003671.s003 (0.05 MB
DOC)
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